Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79419.041.1453%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

InspireMD Inc

NSPRNASDAQ
Trade with Public
Trade with Public
$0.8532
0.01071.27%
At close: Sep 4, 5:00 PM EST
$0.8772
0.0242.81%
After Hours: Sep 4, 7:48 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

InspireMD Analyst Price Targets

Wall Street analyst price targets and consensus rating for InspireMD (NSPR).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$4Upside to Avg. PT+356.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 5, 2026Piper SandlerAdam MaederPT CutOverweight$4→$3
May 12, 2025Piper SandlerAdam MaederPT CutOverweight$5→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on InspireMD, Lowers Price Target to $4

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4.5 to $4.
Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

Lake Street analyst Frank Takkinen initiates coverage on InspireMD (NASDAQ:NSPR) with a Buy rating and announces Price Target of $5.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and maintains $4.5 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5

Piper Sandler analyst Adam Maeder maintains InspireMD (NASDAQ:NSPR) with a Overweight and raises the price target from $3.5 to $4.5.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023

Benzinga Insights

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved